Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1981 Dec;78(12):7707–7711. doi: 10.1073/pnas.78.12.7707

Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

C W Vogel, H J Müller-Eberhard
PMCID: PMC349339  PMID: 6950410

Abstract

The unique specificity of monoclonal antibodies (Ab) was combined with the cell-killing function of the cytolytic alternative pathway of complement. The functionally C3b-like glycoprotein of cobra venom was linked to a murine monoclonal Ab directed to a human melanoma-associated antigen by a disulfide bond, by using a heterobifunctional crosslinking reagent. The covalent monoclonal Ab-cobra venom factor (CVF) complex exhibited specific cytolytic activity in the presence of normal or C4-deficient serum. It induced killing of melanoma cells but not of LG-2 lymphoblastoid cells or P815 mastocytoma cells. The cytolytic action of the monoclonal Ab-CVF complex was selective in that it was limited to the melanoma cells when these were mixed with one of the two other cell lines. In absence of serum, the complex was noncytotoxic. Monoclonal Ab or CVF alone had no cytolytic activity with or without serum. It is concluded that CVF covalently linked to melanoma cell-bound AB forms the stable C3/C5 convertase with factors B and D of the alternative pathway, which in turn causes formation of the membrane attack complex and thereby cell death.

Full text

PDF

Images in this article

7708Image
on p.7708
7708Image
on p.7708
7710Image
on p.7710

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper C. A., Balavitch D. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science. 1976 Mar 26;191(4233):1275–1276. doi: 10.1126/science.56780. [DOI] [PubMed] [Google Scholar]
  2. Ballow M., Cochrane C. G. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J Immunol. 1969 Nov;103(5):944–952. [PubMed] [Google Scholar]
  3. Bianco C., Götze O., Cohn Z. A. Regulation of macrophage migration by products of the complement system. Proc Natl Acad Sci U S A. 1979 Feb;76(2):888–891. doi: 10.1073/pnas.76.2.888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carlsson J., Drevin H., Axén R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J. 1978 Sep 1;173(3):723–737. doi: 10.1042/bj1730723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cochrane C. G., Müller-Eberhard H. J., Aikin B. S. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol. 1970 Jul;105(1):55–69. [PubMed] [Google Scholar]
  6. Daha M. R., Fearon D. T., Austen K. F. C3 requirements for formation of alternative pathway C5 convertase. J Immunol. 1976 Aug;117(2):630–634. [PubMed] [Google Scholar]
  7. Fraker P. J., Speck J. C., Jr Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978 Feb 28;80(4):849–857. doi: 10.1016/0006-291x(78)91322-0. [DOI] [PubMed] [Google Scholar]
  8. Ghose T., Blair A. H. Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects. J Natl Cancer Inst. 1978 Sep;61(3):657–676. [PubMed] [Google Scholar]
  9. Gilliland D. G., Steplewski Z., Collier R. J., Mitchell K. F., Chang T. H., Koprowski H. Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci U S A. 1980 Aug;77(8):4539–4543. doi: 10.1073/pnas.77.8.4539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hugli T. E., Müller-Eberhard H. J. Anaphylatoxins: C3a and C5a. Adv Immunol. 1978;26:1–53. doi: 10.1016/s0065-2776(08)60228-x. [DOI] [PubMed] [Google Scholar]
  11. Kolb W. P., Müller-Eberhard H. J. The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution. J Exp Med. 1973 Aug 1;138(2):438–451. doi: 10.1084/jem.138.2.438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Krolick K. A., Villemez C., Isakson P., Uhr J. W., Vitetta E. S. Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5419–5423. doi: 10.1073/pnas.77.9.5419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lachmann P. J., Halbwachs L. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol. 1975 Jul;21(1):109–114. [PMC free article] [PubMed] [Google Scholar]
  14. Lesavre P. H., Müller-Eberhard H. J. Mechanism of action of factor D of the alternative complement pathway. J Exp Med. 1978 Dec 1;148(6):1498–1509. doi: 10.1084/jem.148.6.1498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McCabe R. P., Quaranta V., Frugis L., Ferrone S., Reisfeld R. A. A radioimmunometric antibody-binding assay for evaluation of xenoantisera to melanoma-associated antigens. J Natl Cancer Inst. 1979 Mar;62(3):455–463. doi: 10.1093/jnci/62.3.455. [DOI] [PubMed] [Google Scholar]
  16. Medicus R. G., Götze O., Müller-Eberhard H. J. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med. 1976 Oct 1;144(4):1076–1093. doi: 10.1084/jem.144.4.1076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Medicus R. G., Götze O., Müller-Eberhard H. J. The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways. Scand J Immunol. 1976;5(9):1049–1055. doi: 10.1111/j.1365-3083.1976.tb03056.x. [DOI] [PubMed] [Google Scholar]
  18. Miyama A., Kato T., Horai S., Yokoo J., Kashiba S. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex. Biken J. 1975 Dec;18(4):193–204. [PubMed] [Google Scholar]
  19. Morgan A. C., Jr, Galloway D. R., Jensen F. C., Giovanella B. C., Reisfeld R. A. Immunochemical delineation of an oncofetal antigen on normal and simian virus 40-transformed human fetal melanocytes. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3834–3838. doi: 10.1073/pnas.78.6.3834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Morgan A. C., Jr, Galloway D. R., Reisfeld R. A. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma. 1981;1(1):27–36. doi: 10.1089/hyb.1.1981.1.27. [DOI] [PubMed] [Google Scholar]
  21. Müller-Eberhard H. J., Schreiber R. D. Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol. 1980;29:1–53. doi: 10.1016/s0065-2776(08)60042-5. [DOI] [PubMed] [Google Scholar]
  22. Pangburn M. K., Schreiber R. D., Müller-Eberhard H. J. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med. 1977 Jul 1;146(1):257–270. doi: 10.1084/jem.146.1.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Schreiber R. D., Müller-Eberhard H. J. Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins. J Exp Med. 1978 Dec 1;148(6):1722–1727. doi: 10.1084/jem.148.6.1722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schreiber R. D., Pangburn M. K., Lesavre P. H., Müller-Eberhard H. J. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3948–3952. doi: 10.1073/pnas.75.8.3948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Schreiber R. D., Pangburn M. K., Medicus R. G., Müller-Eberhard H. J. Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. Clin Immunol Immunopathol. 1980 Mar;15(3):384–396. doi: 10.1016/0090-1229(80)90050-1. [DOI] [PubMed] [Google Scholar]
  26. Thorpe P. E., Brown A. N., Ross W. C., Cumber A. J., Detre S. I., Edwards D. C., Davies A. J., Stirpe F. Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin. Eur J Biochem. 1981 Jun 1;116(3):447–454. doi: 10.1111/j.1432-1033.1981.tb05356.x. [DOI] [PubMed] [Google Scholar]
  27. Vogt W., Dieminger L., Lynen R., Schmidt G. Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement. Hoppe Seylers Z Physiol Chem. 1974 Feb;355(2):171–183. doi: 10.1515/bchm2.1974.355.1.171. [DOI] [PubMed] [Google Scholar]
  28. Whaley K., Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med. 1976 Nov 2;144(5):1147–1163. doi: 10.1084/jem.144.5.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES